Induction chemotherapy with docetaxel and cisplatin followed by concomitant chemoradiotherapy in patients with inoperable non-nasopharyngeal carcinoma of the head and neck.
Title | Induction chemotherapy with docetaxel and cisplatin followed by concomitant chemoradiotherapy in patients with inoperable non-nasopharyngeal carcinoma of the head and neck. |
Publication Type | Journal Article |
Year of Publication | 2009 |
Authors | Fountzilas, G., Bamias A., Kalogera-Fountzila A., Karayannopoulou G., Bobos M., Athanassiou E., Kalogeras K. T., Tolis C., Tsekeris P., Papakostas P., Vamvouka C., Zaramboukas T., Kosmidis P., Zamboglou N., & Misailidou D. |
Journal | Anticancer Res |
Volume | 29 |
Issue | 2 |
Pagination | 529-38 |
Date Published | 2009 Feb |
ISSN | 0250-7005 |
Keywords | Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell, Cisplatin, Combined Modality Therapy, Disease-Free Survival, Female, Gene Amplification, Genes, erbB-2, Head and Neck Neoplasms, Humans, In Situ Hybridization, Fluorescence, Male, Middle Aged, Remission Induction, Taxoids |
Abstract | BACKGROUND: Induction chemotherapy (IC) followed by concomitant chemoradiotherapy (CCRT) has the potential of being an ideal multi-modality approach for improving the prognosis of patients with squamous cell carcinoma of the head and neck (SSCHN).PATIENTS AND METHODS: Thirty-four patients with locally advanced SCCHN were treated with 3 cycles of IC, consisting of docetaxel 75 mg/m2 and cisplatin 75 mg/m2 every 3 weeks, followed 3-4 weeks later by definitive radiotherapy (70 Gy) and concomitant weekly cisplatin 40 mg/m2.RESULTS: After a median follow-up of 27.7 months, 6-month progression-free survival (PFS), the primary study end-point, was 84%. The median PFS was 16.4 months and median overall survival 24.4 months. The majority of the patients completed 3 cycles to moderate toxicity. Anemia, nausea/vomiting and mucositis were the prominent toxicities during CCRT. Retrospective analysis of a panel of biomarkers suggested that excision repair cross-complementation group 1 (ERCC1) protein expression was associated with shorter PFS.CONCLUSION: IC followed by CCRT, as administered in the present study, is a feasible and well-tolerated therapeutic approach. However, its real impact on the prognosis of SCCHN patients has to be demonstrated in a randomized study comparing this treatment to CCRT alone. |
Alternate Journal | Anticancer Res. |
PubMed ID | 19331199 |